Company Overview and News

 
Kenadyr Mining Announces 69 meters at 2.57 g/t Au (including 7 meters at 12.98 g/t Au) in DDH EZ-9-18

2018-09-21 globenewswire
VANCOUVER, British Columbia, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Kenadyr Mining (Holdings) Corp. (TSX-V: KEN; OTC-MKTS: KNDYF; FRA: KM0) (the “Corporation” or “Kenadyr”) is pleased to announce further results of the 2018 drill program at Kenadyr’s Borubai property comprising drill holes EZ- 6,9,10,11,12,13,14 and 16 – 18. (Hole EZ-15-18 was abandoned in fault rubble).
ABX KNTNF ABX

 
K92 Announces Further High-Grade Kora Drill Results from Kora Northern Extension

2018-09-12 globenewswire
K92 Mining Inc. (TSX-V: KNT; OTCQX: KNTNF) (“K92” or the “Company”) is pleased to announce results from the continuing diamond drilling of the Kora North Extension.
KNTNF

 
K92 Mining Releases Second Quarter Financial Results and Confirms 2018 Production Guidance

2018-08-16 globenewswire
VANCOUVER, British Columbia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (TSX-V: KNT; OTCQX: KNTNF) (the “Company” or “K92”) is pleased to announce second quarter financial results and confirm 2018 production guidance.
KNTNF

6
Cobalt27: Emerging Name, Currently Available At A Discount

2018-08-06 seekingalpha - 2
Cobalt is an essential ingredient for Lithium-ion batteries. Supply is tight and getting tighter. Gaining meaningful direct exposure to cobalt is near-impossible to achieve.
WPM SAND SSL SDDXF ABX OKSWF SNXZF SLW RGLD HIG RNX RNX.WT CBLLF SLW RNKLF KNTNF OR HLPCF OSKGF SCYYF SCY RGL ABX

 
K92 is pleased to announce Q2 2018 production of 10,485 ounces of gold and 128,634 pounds of copper from the Kainantu Gold Copper Mine

2018-07-25 globenewswire
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (TSX-V:KNT) (OTCQX:KNTNF) (“K92”) is pleased to provide an update on operations during Q2 2018 (“Q2”) at its Kainantu Gold Mine in Papua New Guinea.
KNTNF

 
K92 Receives $2.73 Million on Warrants Exercised at $1.05 per Share

2018-07-03 globenewswire
VANCOUVER, British Columbia, July 03, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (TSXV:KNT) (OTCQX:KNTNF) (“K92” or the “Company”) reports that it has received CAN $2.73 million through an exercise of 2.6 million common share purchase warrants, which were exercisable at $1.05 per share.
KNTNF

11
Mr. R. Stuart (Tookie) Angus, LLB, appointed as “M&A” Advisor to the Board of Directors

2018-06-26 accesswire - 2
VANCOUVER, BC / ACCESSWIRE / June 26, 2018 / Doubleview Capital Corp. ("Doubleview") (TSX-V: DBV, OTC PINK: DBLVF) is pleased to announce that Mr. Stuart (Tookie) Angus has been appointed as Mergers and Acquisitions ("M&A") Advisor to the Company's Board of Directors, effective June 26, 2018. Mr. Angus brings over 40 years experience in M & A, structuring and financing significant international exploration, development and mining ventures.
NSU KGC RVRLF KNTNF K FQVLF RMC DBV FQM SMN

 
K92 Announces Further High-Grade Kora Drill Results from Kora Northern Extension

2018-06-04 globenewswire
VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (TSX-V:KNT) (OTCQX:KNTNF) (“K92” or the “Company”) is pleased to announce results from the continuing grade control drilling of the Kora North Extension.
KNTNF

 
K92 Mining Releases First Quarter Financial Results and Provides 2018 Production Guidance

2018-05-18 globenewswire
Note1 - a non-IFRS measure computed in the Company’s MD&A in the non-IFRS performance measures section.
KNTNF

 
K92 Announces Further High-Grade Kora Drill Results from Kora Northern Extension

2018-05-17 globenewswire
VANCOUVER, British Columbia, May 17, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. – (TSX-V:KNT) (OTCQX:KNTNF) (“K92”) is pleased to announce results from the continuing grade control drilling of the Kora North Extension.
KNTNF

10
Nexus Gold Announces Management and Board Changes

2018-05-01 accesswire
VANCOUVER, BC / ACCESSWIRE / May 1, 2018 / Nexus Gold Corp. (''Nexus'' or the ''Company'') (TSX-V: NXS; OTC PINK: NXXGD; FSE: N6E) reports the following management and board changes:
AULGF GFI.WI NXXGF NXS KNTNF AU GFI AGG NXXGD GFIOF

 
K92 Mining to Commence Trading on OTCQX

2018-05-01 globenewswire
VANCOUVER, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or “the Company”) (TSXV: KNT) (OTCQX:KNTNF) is pleased to announce that, at the opening of trading on May 1, 2018, it will begins trading on OTCQX under the symbol “KNTNF.” K92 has qualified to trade on the OTCQX® Best Market in the United States. OTCQX is reserved for companies that meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.
KNTNF

 
K92 Mining Announces Stock Options Grant

2018-04-30 globenewswire
VANCOUVER, British Columbia, April 30, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or “the Company”) (TSXV:KNT) (OTCQB:KNTNF) announces the grant of 2,230,000 stock options to directors, officers, employees and consultants of the Company, pursuant to the terms of the Company’s Stock Option Plan. The options are exercisable at $0.85 per share, expire on April 30, 2023, and vest in quarterly increments over 12 months from the date of grant.
KNTNF

1
K92 Announces Record High-Grade Kora Drill Results from Kora Northern Extension including 5.82 m at 486.78 g/t Au, 21 g/t Ag and 0.15% Cu (487.1 g/t AuEq) in hole KMDD0084

2018-04-25 globenewswire - 1
VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92”) (TSXV:KNT) (OTCQB:KNTNF) is pleased to announce results from the continuing grade control drilling of the Kora North Extension.
KNTNF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...